- 1 Supplementary: Modeling impact and cost-effectiveness of gene drives for malaria elimination in the Democratic Republic of the
- 2 Congo
- 3 <u>Supplementary 1</u>, Non-spatial simulation framework: number and frequency of driving-Y gene-drive mosquitoes released.



4 Baseline observed throughout 15-year simulation timeframe in the spatial framework of eight study locations: Haut Katanga Kasai Central Kinshasa



7 Simulation outputs by site:

Bas Uele



Equateur



Haut Katanga



Kasai Central



Kinshasa



Kwango



Nord Ubangui



Supplementary 2, Non-spatial simulation framework: driving-Y parameters of gene-drive mosquitoes single release at year 0.

Basuele





Haut Katanga

0.0 0.1 0.2 0.3 0.4 0.5

Fecundity Reduction

Post-release of 100 gene-drive mosquitoes Year 5 Year 10 Year 15 1.0 1.0 Parasite Prevalence X-shredding Rate 0.9 0.8 0.5 0.7 0.6 0.5 0.0 0.0 0.1 0.2 0.3 0.4 0.5 0.0 0.1 0.2 0.3 0.4 0.5 0.0 0.1 0.2 0.3 0.4 0.5 Post-release of 200 gene-drive mosquitoes Year 15 Year 5 Year 10 1.0 1.0 Parasite Prevalence X-shredding Rate 0.9 0.8 0.5 0.7 0.6 0.5 0.0 0.0 0.1 0.2 0.3 0.4 0.5 0.0 0.1 0.2 0.3 0.4 0.5 0.0 0.1 0.2 0.3 0.4 0.5 Post-release of 300 gene-drive mosquitoes Year 5 Year 10 Year 15 1.0 1.0 Parasite Prevalence X-shredding Rate 0.9 0.8 0.5 0.7 0.6 0.5 0.0

0.0 0.1 0.2 0.3 0.4 0.5

Fecundity Reduction

0.0 0.1 0.2 0.3 0.4 0.5

Fecundity Reduction

Kasai Central



Kinshasa







23 24

25

Supplementary 3, Non-spatial simulation framework: ratio between current and initial numbers of adult vectors, 15-year post- single release of 300 drive mosquitoes at year 0.



27 <u>Supplementary 4</u>: Spatial simulation framework: simulation outputs.

Bas Uele - scenarios without gene drives





Bas Uele - scenarios with 300 gene drives released at year 0



Equateur - scenarios without gene drives



Equateur - scenarios with 300 gene drives at year 0



Haut Katanga - scenarios without gene drives



Haut Katanga - scenarios with 300 gene drives released at year 0





Kasai Central - scenarios without gene drives



Kasai Central - scenarios with 300 gene drives released at year 0



Kinshasa - scenarios without gene drives



Kinshasa - scenarios with 300 gene drives released at year 0



Kwango - scenarios without gene drives



Kwango - scenarios with 300 gene drives released at year 0



Nord Ubangui - scenarios without gene drives





43 <u>Supplementary 5: Reduced migration testing</u>

Vector migration multiplier = 0.01 Vector migration multiplier = 0.001 Vector migration multiplier = 0.0001



X-shredding rate 0.95 and 1.0, *X-shredding rate 0.9, 0.95, and 1.0 Vector migration multiplier = 0.01 Vector migration multiplier = 0.001 Vector migration multiplier = 0.0001

46 <u>Supplementary 6</u>: Cost-effectiveness analysis

47

48 <u>Table S1</u> Average DALYs averted per year per one million population across all locations estimated from

49 model's outputs in spatial simulation framework. Estimates of each scenario were compared with baseline

50 scenario, which 50% ITNs and 19% ACT coverage were applied. For scenarios that included gene drives,

51 only the estimates from scenarios that resulted in malaria elimination were included.

			Average DA	LYs averted per y	ear per one millior	n population
				Model's	estimates	
	Intervention	Coverage	Average over 15 years	The first interval:	The second interval:	The last interval:
				year 1-5	year 0-10	year 11-15
	ITNs	50%	-3,696	-6,818	-2,361	-1,910
	11105	80%	1,482	12,827	-1,990	-6,390
out		95%	8,727	27,165	2,158	-3,143
vith ives	ACT	50%	1,680	-7,733	2,506	10,266
os v s dri	ACT	80%	12,962	10,390	10,212	18,283
Scenario gene		95%	21,437	25,261	15,883	23,169
Scei		50%	8,004	14,973	4,432	4,606
	TINS & ACT	80%	33,477	60,693	21,288	18,451
		95%	72,706	81,875	69,014	67,230
	300 gene drive mosquitoes with X- shredding rates = 1.0 alone	NA	57,298	2,888	82,542	86,464
se	ITNs plus gene drives with X- shredding rates = 0.95 and 1.0	80	57,561	12,201	81,580	78,904
ae drive	ITNs plus gene drives with X- shredding rates = 0.95 and 1.0	95	68,222	43,505	75,420	85,741
vith ger	ACT plus gene drives with X- shredding rates = 0.95 and 1.0	95	68,006	40,162	83,090	80,766
arios w	ITNs & ACT plus gene drives with X-shredding rates = 0.95 and 1.0	50	67,740	39,311	83,142	80,766
Scen	ITNs & ACT plus gene drives with X-shredding rates = 0.95 and 1.0	80	81,029	73,234	82,414	87,441
	ITNs & ACT plus gene drives with X-shredding rates = 0.9, 0.95 and 1.0	95	85,307	86,609	81,819	87,492

Notes for Table S1:

1) NA: Not applicable

2) Green highlight: the scenario achieved malaria elimination

3) It is possible that the DALY averted results turned out to be negative figures in some scenarios since the combination of ITNs at 50% coverage and ACT at 19% coverage was applied in the baseline scenarios that were used as a comparator to reflect reality. For example, a 50% ITNs scenario means only ITNs at 50% coverage was applied as a single intervention in the scenario. Therefore, it is understandable that the lower efficacy of 50% ITNs alone could be observed once compared to the comparator in which the combination of 50% ITNs and 19% ACT was applied. Negative DALYs averted are in red texts.

52 53

54 55

56

57

58

59

60

61

62

4) WHO estimated the DALYs averted using null (do nothing) scenario as a comparator.

1 4010	<u>- 52</u> / Weitag	se cost per		verte			Uns a		mom	ation	s app		sumated		er s outputs						
						Scenar	rios wit	hout ge	ene driv	ves						Scenari	os with gene o	lrives			
														Intervention(s)							
				ITNs ACT						The combination of ITNs and ACT				300 gene- drive mosquitoes with X- shredding rates = 1.0 alone	ITNs plus gene drives with X- shredding rates = 0.95 and 1.0	ITNs plus gene drives with X- shredding rates = 0.95 and 1.0	ACT plus gene drives with X- shredding rates = 0.95 and 1.0	ITNs & ACT plus gene drives with X- shredding rates = 0.95 and 1.0	ITNs & ACT plus gene drives with X- shredding rates = 0.95 and 1.0	ITNs & ACT plus gene drives with X- shredding rates = 0.9, 0.95 and 1.0	
														Coverage (%)						
	Parasite prevalence at the end of the 50- year run-in (%)	Coverage (%)	Interval	50	80	95	50	80	95	50	80	95	Bound	NA	80	95	95	50	80	95	
	WHO's	estimates for (4)	Afr E	49	42	41	21	14	12	43	35	28	NA	NA	NA	NA	NA	NA	NA	NA	
		Year	Year	45	22	13	0	1/13	9	28	12	11	Lower bound	-36	111	37	23	36	NA	NA	
			1-5	-43	22	15	-9	143	9	28	12	11	Upper bound	-355	641	NA NA NA NA 37 23 36 NA 205 184 200 NA 26 11 17 NA	NA				
its	7 27	Haut	Year	-	-91	23	13	18	12	303	10	0	Lower bound	9	17	26	11	36 NA 200 NA 17 NA	NA		
outpu	7.27	Katanga	6-10	238	-91	23		10	12	303	10		Upper bound	96	142	89	95	96	NA	NA	
odel's c			Year	-	-121	25	20	12	11	169	10	0	Lower bound	9	17	18	12	17	NA	NA	
rom n			11-15	207	-121	25	20	12	11	109	10	9	Upper bound	99	98	91	97	99	NA	NA	
nates 1	20.81	Kwango	Year	-60	51	26	-24	23	9	17	11	8	Lower bound	-340	NA	32	NA	NA	20	NA	
Estiı	20.01	ixwalig0	1-5	-00	51	20	-24	23	7	+/	11	0	Upper bound	-3,382	NA	175	NA	NA	101	NA	

63 <u>Table S2</u> Average cost per DALY averted of interventions and combinations applied estimated from model's outputs.

			Year	-	494	156	55	17	12	112	50	0	Lower bound	9	NA	17	NA	NA	18	NA	
			6-10	427	-494	-150	55	17	12	112	39	2	Upper bound	85	NA	95	NA	NA	94	NA	
			Year	_	117	106	19	11	0	120	80	0	Lower bound	8	NA	16	NA	NA	18	NA	
			11-15	275	-11/	-100	10	11	9	120	09	0	Upper bound	82	NA	90	NA	NA	91	NA	
			Year	-69	51	26	-29	11	8	46	11	8	Lower bound	11,661	NA	32	NA	NA	20	NA	
	29.65		1-5	-07	51	20	-27	11	0	40	11	0	Upper bound	116,124	NA	176	NA	NA	103	NA	
		Kasai Central	Year	-	-245	-161	64	20	14	157	68	Q	Lower bound	9	NA	18	NA	NA	19	NA	
			6-10	175	-245	-101	04	20	14	157	00		Upper bound	87	NA	97	NA	NA	97	NA	
			Year	-	-102	-81	20	11	9	142	121	9	Lower bound	8	NA	16	NA	NA	18	NA	
			11-15	220	-102	-01	20	11		142	121		Upper bound	83	NA	91	NA	NA	92	NA	
			Year	-64	53	30	-27	20	8	48	11	8	Lower bound	82	NA	31	NA	NA	20	NA	
			1-5	04	55	50		20	0	40	11	0	Upper bound	816	NA	172	NA	NA	102	NA	
	45.03	Nord	Year	-	-925	-206	125	22	15	138	66	Q	Lower bound	9	NA	17	NA	NA	19	NA	
	-5.05	Ubangui	6-10	168	-925	-200	125	22	15	150	00		Upper bound	88	NA	96	NA	NA	98	NA	
			Year	-	-96	-82	17	10	9	129	98	8	Lower bound	8	NA	16	NA	NA	17	NA	
			11-15	419		02	17	10		12)	70	0	Upper bound	82	NA	89	NA	NA	91	NA	
			Year	-81	61	29	-36	19	8	48	12	10	Lower bound	65	NA	NA	NA	NA	20	16	
	51.64	Bas Uele	0-5		01	2)	50	17	8	48	12	10	Upper bound	645	NA	NA	NA	NA	105	87	
					Year 6-10	- 181	-606	-322	117	22	15	140	170	9	Lower bound	9	NA	NA	NA	NA	19

													Upper bound	87	NA	NA	NA	NA	97	96
			Year	-	91	72	10	11	0	180	111	0	Lower bound	8	NA	NA	NA	NA	18	17
			11-15	204	-01	-73	19	11	2	100	111	2	Upper bound	82	NA	NA	NA	NA	91	90
			Year	-	104	51	-89	19	Q	67	17	10	Lower bound	77	NA	NA	NA	NA	25	18
			1-5	103	104	51	-07	17	,	07	17	10	Upper bound	765	NA	NA	NA	NA	129	97
	52 33	Kinchaca	Year	-	-366	-	110	20	13	181	69	23	Lower bound	9	NA	NA	NA	NA	19	18
	52.55	KIIISIIASA	6-10	170	-300	1,602	110	20	15	101	09	23	Upper bound	88	NA	NA	NA	NA	98	97
			Year	-	118	08	18	10	8	1/13	87	36	Lower bound	8	NA	NA	NA	NA	17	17
			11-15	271	-110	-90	10	10	0	145	62	50	Upper bound	81	NA	NA	NA	NA	91	90
			Year	-	76	40	86	17	8	53	40	0	Lower bound	55	NA	NA	NA	NA	23	17
			1-5	104	70	40	-80	17	0	55	40	2	Upper bound	547	NA	NA	NA	NA	120	91
	54 33	Equateur	Year	-	5 157	706	115	21	12	142	75	10	Lower bound	9	NA	NA	NA	NA	19	18
	54.55		6-10	180	5,457	-700	115	21	15	145	15	19	Upper bound	88	NA	NA	NA	NA	98	97
			Year	-	75	74	20	12	0	164	115	21	Lower bound	8	NA	NA	NA	NA	18	17
			11-15	252	-75	-/4	20	12	9	104	115	51	Upper bound	83	NA	NA	NA	NA	92	91
Note	Note for Table S2: 1) NA: Not applicable																			
		2)	The scen	narios	that co	ould acl	hieve	mala	ria el	imina	tion v	when	adding	gene drives	were high	lighted in g	reen.			
		3)	\$int: Inte	ernatio	onal De	ollars							-		-	-				
		4)	upper bo	ound:	upper b	oound p	price,	lowe	r bou	nd: lo	ower b	ooun	d price							

69 Table S3 Incremental cost-effectiveness ratio in year 1-5 after applying intervention(s)

						ICER (\$int per DALY	averted)		
				The first year	interval: • 1-5	The second year (interval: 5-10	The las year	t interval: : 11-15
	Intervention	Coverage	Label	Lower bound	Upper bound	Lower bound	Upper bound	Lower bound	Upper bound
	ITNs	50%	А	dominated	dominated	negative	dominated	negative	dominated
sue		80%	В	dominated	dominated	negative	dominated	negative	dominated
		95%	С	6.52	6.52	negative	dominated	negative	dominated
nou	ACT	50%	D	negative	negative	negative	negative	negative	negative
wit rive		80%	Е	negative	negative	negative	negative	negative	negative
d d		95%	F	First point	First point	negative	First point	negative	First point
enai	ITNs & ACT	50%	G	dominated	dominated	negative	dominated	negative	dominated
NC NC		80%	Н	0.43	0.43	dominated	2.82	dominated	dominated
		95%	Ι	0.23	0.23	dominated	0.25	dominated	0.30
	300 gene drive mosquitoes with X-shredding rates = 1.0 alone	NA	J	dominated	dominated	First point	2.62	First point	2.76
ves	ITNs plus gene drives with X-shredding rates = 0.95 and 1.0	80	K	dominated	dominated	dominated	2.90	dominated	3.42
ene dri	ITNs plus gene drives with X-shredding rates = 0.95 and 1.0	95	L	1.67	10.56	dominated	3.23	dominated	3.07
with g	ACT plus gene drives with X-shredding rates = 0.95 and 1.0	95	М	1.22	12.10	9.74	2.68	dominated	3.12
narios v	ITNs & ACT plus gene drives with X-shredding rates = 0.95 and 1.0	& ACT plus gene drives with X-shredding 50		2.12	13.66	28.36	2.85	dominated	3.33
Sce	ITNs & ACT plus gene drives with X-shredding rates = 0.95 and 1.0	80	0	0.69	4.06	dominated	2.93	20.99	3.03
	ITNs & ACT plus gene drives with X-shredding rates = 0.9, 0.95 and 1.0	95	Р	0.51	3.14	dominated	2.92	17.93	2.99

70 Keys for Table S3:

- 71 ٠ ICER: Incremental cost-effectiveness ratio
- 72 Negative: the incremental cost and the incremental effect are negative ٠ 73
 - Dominated: the incremental cost is positive, and the incremental effect is negative ٠
 - Vector control strategies that could reach malaria elimination were highlighted in green. ٠
- 75 Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in its effectiveness. The first, ٠ 76
 - second, and third points of each expansion path were highlighted in red, orange, and yellow accordingly.

Supplementary 7: Costs of vector control approaches that involve the release of mosquitoes to modify vector population – A systematic scoping review.

79 <u>Background</u>

80 Vector control approaches that involve the release of mosquitoes to modify the vector 81 population range from Wolbachia related technique to sterile insect production using radiation 82 technique (1,2). For Wolbachia related technique, the strategy proposed to infect mosquitoes 83 with Wolbachia endosymbiotic that inhibits the viral replication and dissemination and 84 eventually completely blocks vector-borne disease transmissions (3). The latter strategy, sterile 85 insect technique (SIT) exposes male mosquitoes with low radiation in the laboratory production. 86 This leads to sterilization of the male mosquitoes but maintain their copulation capacity (4). 87 Once released to the environment, the sterile male mosquitoes mate wild female mosquitoes 88 which would produce sterile eggs thereby eliminating the next generation progenies (5). 89 Producing SIT insects at a large scale requires standardized mass-rearing procedures to produce 90 good quality males that could compete with wild males to mate with females in the wild 91 environment (6). Later development of these strategies includes the release of genetically 92 engineered mosquitoes carrying dominant lethal allele that are capable of killing a subsequent 93 generation (7). The produced OX513A mosquitoes are males that once mate with wild female 94 mosquitoes will produce descendants that would not reach the adult stage due to lethal genes 95 (8).

96 It is necessary for the decision to adapt these strategies specifically modifying mosquito 97 vectors to be based on evidence of program effectiveness and cost-effectiveness of the 98 interventions (9,10). However, evidence on costs and cost assessments of these strategies 99 remain disparate. Data on costs could provide invaluable information for implementing vector 100 control programs as malaria and other mosquito-borne infectious diseases continue to be a 101 public health problem despite past and on-going control efforts (10). For sustenance of control 102 efforts to achieve the disease elimination goal, it is important that the most cost-effective 103 interventions are deployed (11). This supplementary is a systematic scoping review on costs and 104 cost analysis of vector control approaches that involve the release of mosquitoes to modify the 105 vector population focusing relevance on mosquito-borne diseases, especially malaria.

106 Methods

A systematic search of literatures in English language pertaining to costs of vector
control methods to modify mosquito populations, published from 2010 to 2020, was performed
(Diagram S1). Databases include National Center for Biotechnology Information (NCBI),
Google Scholar, Crossref, and Scopus. Search terms include 'Culicidae' and 'genetic
engineering' or 'genetically modified' and 'costs' or 'cost analysis' and 'malaria'.

engineering or genetically modified and costs or cost analysis and malaria.

112 3,486 records of the initial search: 761 articles in PubMed Central, 13 articles in 113 PubMed, 22 items in 13 books, 2480 articles in Google Scholar, 200 articles in Crossref, and 10 114 articles in Scopus, were screened for relevance, and those that included some forms of 115 information on costs of new vector control intended to modify mosquito populations were 116 assessed further in full texts for eligibility. 8 articles from reference lists thought to be relevant 117 based on their titles alone were included in the full-text assessment. We excluded 3,428 articles 118 that were duplicated, or full texts not provided. In full-text assessment, 66 articles were included 119 based on selection criteria suggested costs or cost analysis of vector control methods intended to 120 modify mosquito populations were described in monetary terms. 58 publications did not 121 mention costs or mentioned but did not provide estimates in terms of monetary numbers were 122 excluded. Details of literature selection procedures are in Diagram S1.

123 After eligible articles passed to the full-text assessment, we extracted details on 124 publication year, country/region, target development, target disease, costs, the category of costs. 125 Monetary cost data were first adjusted to US\$ in the year of the initial study using historical 126 exchange rates provided in the article if the adjustment was not supplied by the authors. If the 127 currency year was not mentioned in the article, the publication date or date of article submission 128 was used for the currency conversion. All monetary data were standardized to 2000 US\$ using 129 the US government consumer price index (CPI) data to adjust for inflation (12). All costs were 130 adjusted to US\$ value in year 2000 to allow comparison of the costs of interventions across data

131 sources.

132 <u>Diagram S1</u> Search strategy for costing studies



133 134 135 Results

136 Four out of seven eligible records focused on or used data from research conducted in 137 low- and middle-income countries and were published between 2011 and 2018. Most studies focused on Dengue using various techniques including Wolbachia infected mosquitoes, sterile 138 139 insect technique (SIT), Release of Insects carrying Dominant Lethals (RIDL), and Genetically 140 engineered (GE) mosquitoes i.e., Oxitec. Only one study specifically identified cost of in 141 malaria control. One study (13) developed a cost model to calculate costs of genetic RIDL 142 technology for dengue and was referenced by another study (14). In terms of costs, costs of the 143 release of SIT insects range from 29.42 to 800 US\$ (14) per million insects depending on cost 144 categories. The costs of GM mosquitoes are varied and higher at the beginning of release with 145 lower cost during later maintenance phase. Wolbachia infected mosquitoes gives low cost at 146 0.72 US\$ per person. Table S4 summarized the study characteristics and details on costs 147 described in each study.

References	Publicati on year	Country	Target development	Target disease	Target species	Cost originally indicated	Converted cost to year 2000	Category of costs
Khamis D, El Mouden C, Kura K, et al. (14)	2018	Not specified	Sterile insect technique (SIT) mosquitoes	Malaria	Not specified	mean = 9.11 (min = 1.93, max = 25.36) US\$ per 10,000 insect per day	6.25 (1.32, 17.39) US\$ per 10,000 insects per days	Operational costs
O'Neill SL, Ryan PA, Turley AP, Wilson G, Retzki K, Iturbe- Ormaetxe I et al. (15)	2018	Australia	Wolbachia infected mosquitoes	Dengue and other <i>Aedes</i> transmitted arboviruses	Aedes aegypti	<i>Wolbachia</i> infected mosquito: 1.07 US\$ per person	0.72 US\$ per person*	Deployment cost
Meghani Z and BoeÈte C. (16)	2018	Brazil	Genetically engineered (GE) mosquitoes	Dengue	Aedes aegypti	1.9 million US\$ and 384,000US\$ for subsequent years per 50,000 urban populationOxitec: 10 US\$ per person	1.36 million US\$ and 275,511.96 US\$ for subsequent years per 50,000 urban population Oxitec: 7.17 US\$ per	Not specified but mentioned that the costs did not consider recurrent relicensing and subsidizing the
Alfaro-Murillo JA, Parpia AS, Fitzpatrick MC, Tamagnan JA, Medlock J, Ndeffo-Mbah ML, et al. (17)	2016	Middle- income countries (main country: Brazil)	GE mosquitoes (Oxitec)	Zika	Aedes aegypti (male)	(in year 2016) 1.9 million US\$ (in year 2015) in the first year and 384,000 US\$ each year thereafter for an urban population of 50,000	person** 1.38 million US\$ (for 1 st year) and 278,987.58 US\$ per year afterward	cost Not stated

149 <u>Table S4</u> Summary of study characteristics and details on costs of vector control approaches that involve the release of mosquitoes to modify the vector 150 population focusing relevance on mosquito-borne diseases.

References	Publicati on year	Country	Target development	Target disease	Target species	Cost originally indicated	Converted cost to year 2000	Category of costs
Undurraga EA, Halasa YA, Shepard DS. (18)	2016	Brazil, Mexico, Panama, Puerto Rico, and Thailand	Genetic modified (GM) mosquitoes	Dengue	Aedes	25-75 US\$ per person per year in suppression phase and 10-20 US\$ per person per year in maintenance phase, based on preliminary estimates by Oxitec.	17.94-53.81 US\$ per person per year in suppression phase and 7.17**-14.35 US\$ per person per year in maintenance phase	Overall cost estimate
Bellini R, Medici A, Puggioli A, Balestrino F, Carrieri AM. (19)	2013	India	SIT	Arboviral diseases in humans	Aedes albopictus (Skuse)	40 US\$ per million male mosquitoes per day	29.42 US\$ per million male mosquitoes per day	Production cost
Alphey N, Alphey L, and Bonsall MB. (13)	2011	Not specified	Genetic Release of Insects carrying Dominant Lethals (RIDL) technology (Release of Insects carrying a Dominant Lethal)	Dengue	Aedes aegypti	1 US\$ per 1000 insects (in year 2008) 2.30 US\$ per case averted (in year 2008) Mean cost per person protected per year during the assessment period is 0.05– 0.07 US\$ or 0.52–0.68 US\$ (release ratio 1 or 10, respectively in year 2008)	0.80 US\$ per 1,000 insects 1.84 US\$ per case averted Mean cost per person protected per year during the assessment period is 0.04-0.07 US\$ or 0.42-0.54 US\$ (release ratio 1 or 10 respectively)	Construction and operational costs

151 *lower bound cost applied in the main study.

152 **upper bound cost applied in the main study.

153 Discussion

154 During the past 10 years, only handful costing evidence of vector control approaches 155 that involve the release of mosquitoes to modify the vector population focusing relevance on 156 mosquito-borne diseases, especially malaria, has been made available. When costs were 157 mentioned, the studies were often not undertaken alongside an evaluation of the clinical and 158 epidemiological effect of the methods of interest. This systematic scoping review is an early 159 attempt to combine evidence on costs of the approaches.

160 References

- 161 1. Committee on Gene Drive Research in Non-Human Organisms: Recommendations for Responsible 162 Conduct; Board on Life Sciences; Division on Earth and Life Studies; National Academies of Sciences 163 Engineering and Medicine. Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and 164 Aligning Research with Public Values [Internet]. National Academies Press; 2016. Available from: 165 http://www.nap.edu/catalog/23405
- 166 2. Flores HA, O'Neill SL. Controlling vector-borne diseases by releasing modified mosquitoes [Internet]. Vol. 167 16, Nature Reviews Microbiology. Nature Publishing Group; 2018 [cited 2021 Jan 24]. p. 508-18. Available 168 from: https://www.nature.com/articles/s41579-018-0025-0
- 169 Gomes FM, Barillas-Mury C. Infection of Anopheline mosquitoes with Wolbachia: Implications for malaria 3. 170 171 172 173 control [Internet]. Vol. 14, PLoS Pathogens, Public Library of Science; 2018 [cited 2021 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237385/
- Reis NN, Silva AL da, Reis EPG, Silva FC e., Reis IGN. Viruses vector control proposal: genus Aedes 4. emphasis, Vol. 21, Brazilian Journal of Infectious Diseases, Elsevier Editora Ltda; 2017, p. 457-63. 174 5. Reis NN, Silva AL da, Reis EPG, Silva FC e., Reis IGN. Viruses vector control proposal: genus Aedes
 - emphasis. Brazilian Journal of Infectious Diseases [Internet]. 2017;21(4):457-63. Available from: http://dx.doi.org/10.1016/j.bjid.2017.03.020
- 175 176 177 178 179 6. Mamai W, Lobb LN, Bimbilé Somda NS, Maiga H, Yamada H, Lees RS, et al. Optimization of mass-rearing methods for Anopheles arabiensis larval stages: Effects of rearing water temperature and larval density on mosquito life-history traits. Journal of Economic Entomology. 2018;111(5):2383-90.
- 180 7. Hoang PN, Daniel Zucker J, Choisy M, Vinh HT. Causality analysis between climatic factors and dengue 181 fever using the Granger causality. 2016 IEEE RIVF International Conference on Computing and 182 183 Communication Technologies: Research, Innovation, and Vision for the Future, RIVF 2016 - Proceedings. 2016;49-54.
- 184 Wentzel M. Brasil testa duas ' armas ' contra o Aedes aegypti ; saiba quando teremos resultado O mosquito 8. 185 inoculado. BBC News Brasil. 2015;1-9.
- 186 9. WHO. Guidelines for malaria vector control [Internet]. 2019 [cited 2021 Jan 24]. Available from: https://apps.who.int/iris/bitstream/handle/10665/310862/9789241550499-eng.pdf?ua=1
- 187 188 189 WHO. Global Vector Control Response 2017-2030 [Internet]. 2017 [cited 2021 Jan 24]. Available from: 10. https://apps.who.int/iris/bitstream/handle/10665/259205/9789241512978-
- 190 191 192 eng.pdf;jsessionid=BCA2E1473557FBC791074D7675EA2BE3?sequence=1 11. White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions-a systematic review. Malaria journal. 2011 Nov;10:337.
- 193 12. U.S. Bureau of Labor Statistics. 2000 Home : The Economics Daily : U.S. Bureau of Labor Statistics 194 [Internet]. 2000 [cited 2021 Jan 24]. Available from: https://www.bls.gov/opub/ted/2000/home.htm
- 195 13. Alphey N, Alphey L, Bonsall MB. A model framework to estimate impact and cost of genetics-based sterile 196 197 insect methods for dengue vector control. PLoS ONE. 2011;6(10).
- 14. Khamis D, El Mouden C, Kura K, Bonsall MB. Optimal control of malaria: Combining vector interventions 198 and drug therapies. Malaria Journal [Internet]. 2018;17(1):1–18. Available from: 199 https://doi.org/10.1186/s12936-018-2321-6
- 200 15. O'Neill SL, Ryan PA, Turley AP, Wilson G, Retzki K, Iturbe-Ormaetxe I, et al. Scaled deployment of 201 202 Wolbachia to protect the community from dengue and other aedes transmitted arboviruses. Gates Open Research. 2018 Aug 13;2:36.
- 203 16. Meghani Z, Boëte C. Genetically engineered mosquitoes, Zika and other arboviruses, community 204 engagement, costs, and patents: Ethical issues. PLoS Neglected Tropical Diseases. 2018;12(7):1-7.
- 20517. Alfaro-Murillo JA, Parpia AS, Fitzpatrick MC, Tamagnan JA, Medlock J, Ndeffo-Mbah ML, et al. A Cost-206 Effectiveness Tool for Informing Policies on Zika Virus Control. PLoS Neglected Tropical Diseases 207 [Internet]. 2016;10(5):1–14. Available from: http://dx.doi.org/10.1371/journal.pntd.0004743
- $\overline{2}08$ Undurraga EA, Halasa YA, Shepard DS. Economic Analysis of Genetically Modified Mosquito Strategies. 18. 209 In: Genetic Control of Malaria and Dengue. Elsevier Inc.; 2016. p. 375-408.
- 21019. Bellini R, Medici A, Puggioli A, Balestrino F, Carrieri AM. Pilot Field Trials With Aedes albopictus 211 Irradiated Sterile Males in Italian Urban Areas. J Med Entomol [Internet]. 2013 [cited 2021 Jan $\overline{2}\overline{1}\overline{2}$ 24];50(2):317-25. Available from: http://dx.doi.org/10.1603/ME12048